DellaCamera Sends Letter to Enzon Board of Directors

DellaCamera Capital Management, LLC, today delivered a letter to the Board of Directors of Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) stating its ongoing belief that the Company’s stock is significantly undervalued and that it is encouraged by the Company’s present commitment to enhance shareholder value. DellaCamera beneficially owns in excess of 7% of Enzon’s common stock. The full text of the letter follows: Dear Jeff: While we are fully aware of the recent troubles in the financial markets, we believe that the stock of Enzon (the “Company”) has been punished to a degree that borders on the absurd, particularly given the numerous assets owned by the Company coupled with the current, robust demand for biotech/pharmaceutical properties. Furthermore, we are encouraged by the recent steps taken by the Company to explore... [read full story]